These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 38130884)

  • 21. Trimodal therapy in muscle invasive bladder cancer management.
    Polo-Alonso E; Kuk C; Guruli G; Paul AK; Thalmann G; Kamat A; Solsona E; Thalmann G; Urdaneta AI; Zlotta AR; Mir MC
    Minerva Urol Nefrol; 2020 Dec; 72(6):650-662. PubMed ID: 33263367
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinicopathological factors in bladder cancer for cancer-specific survival outcomes following radical cystectomy: a systematic review and meta-analysis.
    Zhang L; Wu B; Zha Z; Qu W; Zhao H; Yuan J
    BMC Cancer; 2019 Jul; 19(1):716. PubMed ID: 31324162
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Survival after sequential neoadjuvant chemotherapy followed by trimodal treatment or radical cystectomy for muscle-invasive bladder cancer.
    Reignier PL; Gauthier H; Hennequin C; Aussedat Q; Xylinas E; Desgrandchamps F; Culine S; Masson-Lecomte A; Dumont C
    World J Urol; 2023 Nov; 41(11):3249-3255. PubMed ID: 37410102
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship of frailty with treatment modality selection in patients with muscle-invasive bladder cancer (FRART-BC study).
    Iwamura H; Hatakeyama S; Momota M; Kojima Y; Narita T; Okamoto T; Fujita N; Hamano I; Togashi K; Hamaya T; Yoneyama T; Yamamoto H; Yoneyama T; Hashimoto Y; Ohyama C
    Transl Androl Urol; 2021 Mar; 10(3):1143-1151. PubMed ID: 33850749
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of Survival Outcomes With Trimodal Therapy as Primary Therapy for Non-organ-confined Bladder Cancer.
    Guo Y; Jie X; Zhang A; Zhang W; Wang R; Zhang J; Mao S; Wu Y; Wang L; Zhang Z; Yan Y; Wang P; Yao X
    Front Oncol; 2019; 9():1315. PubMed ID: 31867271
    [No Abstract]   [Full Text] [Related]  

  • 26. Comparative Effectiveness of Bladder-preserving Tri-modality Therapy Versus Radical Cystectomy for Muscle-invasive Bladder Cancer.
    Royce TJ; Feldman AS; Mossanen M; Yang JC; Shipley WU; Pandharipande PV; Efstathiou JA
    Clin Genitourin Cancer; 2019 Feb; 17(1):23-31.e3. PubMed ID: 30482661
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long term cost comparisons of radical cystectomy versus trimodal therapy for muscle-invasive bladder cancer.
    Golla V; Shan Y; Farran EJ; Stewart CA; Vu K; Yu A; Khaki AR; Parikh DA; Swanson TA; Keegan KA; Kamat AM; Tyler DS; Freedland SJ; Williams SB
    Urol Oncol; 2022 Jun; 40(6):273.e1-273.e9. PubMed ID: 35168881
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients.
    Hamid ARAH; Ridwan FR; Parikesit D; Widia F; Mochtar CA; Umbas R
    BMC Urol; 2020 Oct; 20(1):158. PubMed ID: 33054762
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and network meta-analysis of randomized clinical trials.
    Kim HS; Jeong CW; Kwak C; Kim HH; Ku JH
    Oncotarget; 2017 Oct; 8(46):81204-81214. PubMed ID: 29113380
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association Between Preoperative Hydronephrosis and Prognosis After Radical Cystectomy Among Patients With Bladder Cancer: A Systemic Review and Meta-Analysis.
    Oh JJ; Byun SS; Jeong CW; Kwak C; Kim HH; Ku JH
    Front Oncol; 2019; 9():158. PubMed ID: 30941309
    [No Abstract]   [Full Text] [Related]  

  • 31. Efficiency of bladder-sparing strategies for bladder cancer: an umbrella review.
    Li DX; Yu QX; Wu RC; Wang J; Feng DC; Deng S
    Ther Adv Med Oncol; 2024; 16():17588359241249068. PubMed ID: 38736553
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review.
    Ploussard G; Daneshmand S; Efstathiou JA; Herr HW; James ND; Rödel CM; Shariat SF; Shipley WU; Sternberg CN; Thalmann GN; Kassouf W
    Eur Urol; 2014 Jul; 66(1):120-37. PubMed ID: 24613684
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Concomitant carcinoma in situ may not be a prognostic factor for patients with bladder cancer following radical cystectomy: a PRISMA-compliant systematic review and meta-analysis.
    Zhang L; Wu B; Zha Z; Zhao H; Yuan J; Jiang Y
    World J Urol; 2020 Jan; 38(1):129-142. PubMed ID: 30919100
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incidence and outcome of salvage cystectomy after bladder sparing therapy for muscle invasive bladder cancer: a systematic review and meta-analysis.
    Schuettfort VM; Pradere B; Quhal F; Mostafaei H; Laukhtina E; Mori K; Sari Motlagh R; Fisch M; D'Andrea D; Rink M; Gontero P; Soria F; Shariat SF
    World J Urol; 2021 Jun; 39(6):1757-1768. PubMed ID: 32995918
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of muscle-invasive bladder cancer in patients without comorbidities and fit for surgery: Trimodality therapy vs radical cystectomy. Development of GRADE (Grades of Recommendation, Assessment, Development and Evaluation) recommendation by the Italian Association of Radiotherapy and Clinical Oncology (AIRO).
    Francolini G; Borghesi S; Fersino S; Magli A; Jereczek-Fossa BA; Cristinelli L; Rizzo M; Corvò R; Pappagallo GL; Arcangeli S; Magrini SM; D'Angelillo RM
    Crit Rev Oncol Hematol; 2021 Mar; 159():103235. PubMed ID: 33493633
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer.
    Efstathiou JA; Mouw KW; Gibb EA; Liu Y; Wu CL; Drumm MR; da Costa JB; du Plessis M; Wang NQ; Davicioni E; Feng FY; Seiler R; Black PC; Shipley WU; Miyamoto DT
    Eur Urol; 2019 Jul; 76(1):59-68. PubMed ID: 30712971
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quality of life after definitive treatment for bladder cancer: A systematic review and meta-analysis.
    Francolini G; Ghoshal A; Caini S; Piazzini T; Becherini C; Detti B; Di Cataldo V; Valzano M; Visani L; Salvestrini V; Olmetto E; Desideri I; Meattini I; Livi L
    Radiother Oncol; 2024 Jan; 190():110038. PubMed ID: 38042498
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of Serum Lymphocyte-derived Biomarkers in Nonmetastatic Muscle-invasive Bladder Cancer Patients Treated with Trimodal Therapy.
    Kool R; Marcq G; Shinde-Jadhav S; Mansure JJ; Saleh R; Rajan R; Aprikian A; Tanguay S; Cury FL; Brimo F; Souhami L; Kassouf W
    Eur Urol Open Sci; 2022 Feb; 36():26-33. PubMed ID: 35098169
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Radical cystectomy versus trimodality therapy for muscle-invasive urothelial carcinoma of the bladder.
    Softness K; Kaul S; Fleishman A; Efstathiou J; Bellmunt J; Kim SP; Korets R; Chang P; Wagner A; Olumi AF; Gershman B
    Urol Oncol; 2022 Jun; 40(6):272.e1-272.e9. PubMed ID: 35058142
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quality of Life in Long-term Survivors of Muscle-Invasive Bladder Cancer.
    Mak KS; Smith AB; Eidelman A; Clayman R; Niemierko A; Cheng JS; Matthews J; Drumm MR; Nielsen ME; Feldman AS; Lee RJ; Zietman AL; Chen RC; Shipley WU; Milowsky MI; Efstathiou JA
    Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1028-1036. PubMed ID: 27727064
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.